13 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 13 of 13 clinical reviews.
A clinician-reviewed guide for caregivers managing MK-677 (ibutamoren) use in adolescents aged 12-17, covering dosing, timing, monitoring, side effects, and when to contact a provider.
A detailed clinical review of MK-677 (ibutamoren) off-label use in adults aged 65 and older, covering IGF-1 and GH effects, muscle and bone data, metabolic risks, dosing considerations, and what geriatric patients should discuss with their physician.
A clinician-reviewed guide for caregivers administering MK-677 (ibutamoren) to adults aged 65 and older, covering dosing protocols, safety monitoring, drug interactions, and when to contact a prescriber.
A clinician-reviewed guide to MK-677 (ibutamoren) use in adolescents ages 12 to 17, covering growth hormone axis effects, safety concerns, and the critical steps for transitioning young patients to adult endocrine care.
A physician-reviewed look at off-label MK-677 (ibutamoren) use in adolescents ages 12 to 17, covering growth hormone physiology, clinical trial data, safety signals, and why prescribers avoid this drug in minors.
What adolescents, parents, and clinicians need to know about MK-677 (ibutamoren) use during the school years, including effects on cognition, sleep, sports eligibility, and physical activity safety.
A physician-reviewed guide to MK-677 (ibutamoren) use in geriatric patients, covering pharmacology, dosing, risks, monitoring, and the transition from adult to geriatric care protocols.
A clinical guide to MK-677 (ibutamoren) use in geriatric patients, covering physical activity compatibility, cognitive engagement, fall risk, dosing, and safety data from named trials.
A comprehensive clinical review of MK-677 (ibutamoren) use in pediatric patients under age 12, covering developmental risks, growth hormone axis effects, IGF-1 elevation, insulin resistance, and why no regulatory body has approved ibutamoren for children.
A clinician-reviewed guide covering MK-677 (ibutamoren) use in pediatric patients under age 12, including how the drug affects school performance, physical activity, sleep schedules, and growth plate safety.
A comprehensive review of MK-677 (ibutamoren) off-label use in pediatric patients under age 12, covering the pharmacology, clinical trial evidence, safety concerns, regulatory status, and when growth hormone secretagogues may or may not be appropriate.
A clinician-reviewed caregiver guide to MK-677 (ibutamoren) in children under 12, covering safety data, dosing considerations, regulatory status, and when to contact a prescriber.
A clinician-focused guide to transitioning pediatric patients under age 12 who have received MK-677 (ibutamoren) into adult GH-axis care protocols, covering safety data, regulatory status, dosing, and monitoring frameworks.